New Developments in Myeloma Treatment and Response Assessment.

"Financial Disclosure: This work has been supported in part by grants from the French National Agency for Research “France 2030 investment plan” Labex IRON (ANR-11-LABX-18-01), Equipex ArronaxPlus (ANR-11-EQPX-0004), and I-SITE NExT (ANR-16-IDEX-0007) and by a grant from INCa-DGOS-INSERM_12558 (SIRIC ILIAD). Dr. Moreau has received honoraria from or is on the advisory boards for Janssen, Celgene, Sanofi, Abbvie, Takeda, Amgen, and GSK. Dr. Nanni is a consultant for Sanofi-Aventis, a case revisor for Keosys, and on the advisory board for the EANM Oncology Theranostic Committee and the AIMN Oncology Committee. Dr. Kraeber-Bodéré is a consultant for PentixaPharm and Novartis-AAA, a case revisor for Keosys, and a member of the EANM Oncology Theranostic Committee. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest."

"Financial Disclosure: This work has been supported in part by grants from the French National Agency for Research “France 2030 investment plan” Labex IRON (ANR-11-LABX-18-01), Equipex ArronaxPlus (ANR-11-EQPX-0004), and I-SITE NExT (ANR-16-IDEX-0007) and by a grant from INCa-DGOS-INSERM_12558 (SIRIC ILIAD). Dr. Moreau has received honoraria from or is on the advisory boards for Janssen, Celgene, Sanofi, Abbvie, Takeda, Amgen, and GSK. Dr. Nanni is a consultant for Sanofi-Aventis, a case revisor for Keosys, and on the advisory board for the EANM Oncology Theranostic Committee and the AIMN Oncology Committee. Dr. Kraeber-Bodéré is a consultant for PentixaPharm and Novartis-AAA, a case revisor for Keosys, and a member of the EANM Oncology Theranostic Committee. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest."